...
search icon
roiv-img

Roivant Sciences Ltd, Common Stock

ROIV

NSQ

$11.13

-$0.24

(-2.11%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$8.15B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
2.0523
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.56M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.24
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$9.69 L
$13.05 H
$11.13

About Roivant Sciences Ltd, Common Stock

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameROIVSectorS&P500
1-Week Return-0.45%1.77%-0.48%
1-Month Return-6%6.76%3.25%
3-Month Return-3.72%-6.43%
6-Month Return2.49%-1.84%9.96%
1-Year Return11.2%4.62%25.34%
3-Year Return60%11.92%34.47%
5-Year Return6.92%48.14%88.14%

Financials

Mar '20Mar '21Mar '22Mar '23Mar '245YR TREND
Total Revenue67.69M23.80M55.29M61.28M124.80M[{"date":"2020-03-31","value":54.24,"profit":true},{"date":"2021-03-31","value":19.07,"profit":true},{"date":"2022-03-31","value":44.3,"profit":true},{"date":"2023-03-31","value":49.1,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Cost of Revenue1.13M2.06M8.97M13.13M27.96M[{"date":"2020-03-31","value":4.04,"profit":true},{"date":"2021-03-31","value":7.36,"profit":true},{"date":"2022-03-31","value":32.06,"profit":true},{"date":"2023-03-31","value":46.95,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Gross Profit66.56M21.74M46.32M48.15M96.83M[{"date":"2020-03-31","value":68.74,"profit":true},{"date":"2021-03-31","value":22.45,"profit":true},{"date":"2022-03-31","value":47.84,"profit":true},{"date":"2023-03-31","value":49.73,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Gross Margin98.33%91.36%83.78%78.58%77.59%[{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":92.91,"profit":true},{"date":"2022-03-31","value":85.21,"profit":true},{"date":"2023-03-31","value":79.91,"profit":true},{"date":"2024-03-31","value":78.91,"profit":true}]
Operating Expenses598.98M1.09B1.40B1.22B(4.13B)[{"date":"2020-03-31","value":42.85,"profit":true},{"date":"2021-03-31","value":78.16,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":87.52,"profit":true},{"date":"2024-03-31","value":-295.63,"profit":false}]
Operating Income(532.42M)(1.07B)(1.35B)(1.18B)4.24B[{"date":"2020-03-31","value":-12.55,"profit":false},{"date":"2021-03-31","value":-25.25,"profit":false},{"date":"2022-03-31","value":-31.86,"profit":false},{"date":"2023-03-31","value":-27.71,"profit":false},{"date":"2024-03-31","value":100,"profit":true}]
Total Non-Operating Income/Expense-170.96M421.22M(45.30M)123.06M[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":40.59,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-10.75,"profit":false},{"date":"2024-03-31","value":29.22,"profit":true}]
Pre-Tax Income(560.99M)(898.55M)(923.75M)(1.22B)4.25B[{"date":"2020-03-31","value":-13.19,"profit":false},{"date":"2021-03-31","value":-21.13,"profit":false},{"date":"2022-03-31","value":-21.72,"profit":false},{"date":"2023-03-31","value":-28.8,"profit":false},{"date":"2024-03-31","value":100,"profit":true}]
Income Taxes7.12M1.69M369.00K5.19M22.22M[{"date":"2020-03-31","value":32.06,"profit":true},{"date":"2021-03-31","value":7.59,"profit":true},{"date":"2022-03-31","value":1.66,"profit":true},{"date":"2023-03-31","value":23.35,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Income After Taxes-(900.23M)(924.12M)(1.23B)4.23B[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-21.28,"profit":false},{"date":"2022-03-31","value":-21.84,"profit":false},{"date":"2023-03-31","value":-29.07,"profit":false},{"date":"2024-03-31","value":100,"profit":true}]
Income From Continuous Operations-(900.23M)(924.12M)(1.23B)4.23B[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":-21.28,"profit":false},{"date":"2022-03-31","value":-21.84,"profit":false},{"date":"2023-03-31","value":-29.07,"profit":false},{"date":"2024-03-31","value":100,"profit":true}]
Income From Discontinued Operations1.58B114.56M114.56M114.56M-[{"date":"2020-03-31","value":100,"profit":true},{"date":"2021-03-31","value":7.26,"profit":true},{"date":"2022-03-31","value":7.26,"profit":true},{"date":"2023-03-31","value":7.26,"profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Net Income1.20B(809.23M)(845.26M)(1.01B)4.35B[{"date":"2020-03-31","value":27.6,"profit":true},{"date":"2021-03-31","value":-18.61,"profit":false},{"date":"2022-03-31","value":-19.44,"profit":false},{"date":"2023-03-31","value":-23.2,"profit":false},{"date":"2024-03-31","value":100,"profit":true}]
EPS (Diluted)(0.27)0.36(1.28)(1.59)(1.27)[{"date":"2020-03-31","value":-74.86,"profit":false},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":-355.56,"profit":false},{"date":"2023-03-31","value":-441.67,"profit":false},{"date":"2024-03-31","value":-352.78,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ROIV
Cash Ratio 9.70
Current Ratio 10.43
Quick Ratio 10.78

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ROIV
ROA (LTM) -18.44%
ROE (LTM) 128.96%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ROIV
Debt Ratio Lower is generally better. Negative is bad. 0.10
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.90

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ROIV
Trailing PE 2.01
Forward PE NM
P/S (TTM) 62.74
P/B 1.57
Price/FCF NM
EV/R 21.44
EV/Ebitda 0.67

FAQs

What is Roivant Sciences Ltd share price today?

Roivant Sciences Ltd (ROIV) share price today is $11.13

Can Indians buy Roivant Sciences Ltd shares?

Yes, Indians can buy shares of Roivant Sciences Ltd (ROIV) on Vested. To buy Roivant Sciences Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ROIV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Roivant Sciences Ltd be purchased?

Yes, you can purchase fractional shares of Roivant Sciences Ltd (ROIV) via the Vested app. You can start investing in Roivant Sciences Ltd (ROIV) with a minimum investment of $1.

How to invest in Roivant Sciences Ltd shares from India?

You can invest in shares of Roivant Sciences Ltd (ROIV) via Vested in three simple steps:

  • Click on Sign Up or Invest in ROIV stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Roivant Sciences Ltd shares
What is Roivant Sciences Ltd 52-week high and low stock price?

The 52-week high price of Roivant Sciences Ltd (ROIV) is $13.05. The 52-week low price of Roivant Sciences Ltd (ROIV) is $9.69.

What is Roivant Sciences Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Roivant Sciences Ltd (ROIV) is 2.0523

What is Roivant Sciences Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Roivant Sciences Ltd (ROIV) is 1.57

What is the Market Cap of Roivant Sciences Ltd?

The market capitalization of Roivant Sciences Ltd (ROIV) is $8.15B

What is Roivant Sciences Ltd’s stock symbol?

The stock symbol (or ticker) of Roivant Sciences Ltd is ROIV

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top